Evidence map›Paper›PMID 36543932›Full record

ArticleEuropean journal of human genetics : EJHG2023

Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease.

Leire Torices, Janire Mingo, Isabel Rodríguez-Escudero, Teresa Fernández-Acero, Sandra Luna, Caroline E Nunes-Xavier, José I López, Fátima Mercadillo, María Currás, Miguel Urioste and 3 more

Open access · greenAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular explanations for variability of clinical phenotypes.European journal of human genetics : EJHG · 2023
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Leire ToricesBiocruces Bizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0003-2315-1218
Janire MingoBiocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Isabel Rodríguez-EscuderoDepartamento de Microbiología y Parasitología, Facultad de Farmacia, UCM & Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain.
Teresa Fernández-AceroDepartamento de Microbiología y Parasitología, Facultad de Farmacia, UCM & Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain.
Sandra LunaBiocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Caroline E Nunes-XavierBiocruces Bizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-1875-6645
José I LópezBiocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Fátima MercadilloFamilial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
María CurrásFamilial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Miguel UriosteFamilial Cancer Clinical Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
María MolinaDepartamento de Microbiología y Parasitología, Facultad de Farmacia, UCM & Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain.ORCID 0000-0003-0074-3309
Víctor J CidDepartamento de Microbiología y Parasitología, Facultad de Farmacia, UCM & Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS), Madrid, Spain.
Rafael PulidoBiocruces Bizkaia Health Research Institute, Barakaldo, Spain. rpulidomurillo@gmail.com.ORCID 0000-0001-9100-248X
BioCruces Health research Institute · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESSpanish National Cancer Research Centre · ESIkerbasque · ESOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterozygous germline mutations in PTEN gene predispose to hamartomas and tumors in different tissues, as well as to neurodevelopmental disorders, and define at genetic level the PTEN Hamartoma Tumor Syndrome (PHTS). The major physiologic role of PTEN protein is the dephosphorylation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), counteracting the pro-oncogenic function of phosphatidylinositol 3-kinase (PI3K), and PTEN mutations in PHTS patients frequently abrogate PTEN PIP3 catalytic activity. PTEN also displays non-canonical PIP3-independent functions, but their involvement in PHTS pathogeny is less understood. We have previously identified and described, at clinical and genetic level, novel PTEN variants of unknown functional significance in PHTS patients. Here, we have performed an extensive functional characterization of these PTEN variants (c.77 C > T, p.(Thr26Ile), T26I; c.284 C > G, p.(Pro95Arg), P95R; c.529 T > A, p.(Tyr177Asn), Y177N; c.781 C > G, p.(Gln261Glu), Q261E; c.829 A > G, p.(Thr277Ala), T277A; and c.929 A > G, p.(Asp310Gly), D310G), including cell expression levels and protein stability, PIP3-phosphatase activity, and subcellular localization. In addition, caspase-3 cleavage analysis in cells has been assessed using a C2-domain caspase-3 cleavage-specific anti-PTEN antibody. We have found complex patterns of functional activity on PTEN variants, ranging from loss of PIP3-phosphatase activity, diminished protein expression and stability, and altered nuclear/cytoplasmic localization, to intact functional properties, when compared with PTEN wild type. Furthermore, we have found that PTEN cleavage at the C2-domain by the pro-apoptotic protease caspase-3 is diminished in specific PTEN PHTS variants. Our findings illustrate the multifaceted molecular features of pathogenic PTEN protein variants, which could account for the complexity in the genotype/phenotype manifestations of PHTS patients.

Indexed as

Hamartoma Syndrome, MultiplePTEN PhosphohydrolaseCaspase 3Germ-Line MutationHumansPhosphatidylinositol 3-KinasesCaspase 3Phosphatidylinositol 3-KinasesPTEN PhosphohydrolasePTEN protein, human

Identifiers

PMID36543932
PMCPMC10172195
OpenAlexW4312094955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.